FDA Approval of Zanubrutinib (ALPINE & SEQUOIA Study)

home / pivotal-practice-views-with-the-oncology-brothers / fda-approval-of-zanubrutinib-alpine-and-sequoia-study

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the FDA approval of zanubrutinib and where it fits in clinical practice, highlighting data from the ALPINE and SEQUOIA studies.

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 1: SEQUOIA: Zanubrutinib vs BR in First-Line CLL/SLL

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH
March 15th 2024

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the SEQUOIA trial investigating zanubrutinib vs bendamustine-rituximab in first-line CLL/SLL.

Watch

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 2: ALPINE: Zanubrutinib or Ibrutinib in Relapsed/Refractory CLL

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH
March 15th 2024

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Mazyar Shadman, MD, MPH, to discuss the ALPINE study looking at zanubrutinib vs ibrutinib in relapsed or refractory CLL.

Watch

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 3: Efficacy of Zanubrutinib vs Acalabrutinib in R/R CLL: A Matching-Adjusted Indirect Comparison

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH
March 15th 2024

A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Watch

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 4: Zanubrutinib Safety Profile in CLL

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH
March 15th 2024

Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.

Watch

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

EP. 5: Key Takeaways on Zanubrutinib Data

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH
March 15th 2024

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.

Watch